India's Race For Lipitor: More Than Five Players May Blunt Generic Gains In Post-Exclusivity Period
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Two years after Pfizer Inc. filed a patent infringement lawsuit against India's Dr. Reddy's Laboratories Ltd. in a bid to ward off threats to its blockbuster brand Lipitor (atorvastatin), the two companies filed a joint motion Aug. 19 to dismiss the case at the U.S. District Court of Delaware. The case was dismissed Aug. 29 but the terms and conditions of the settlement and a likely launch date for the generic versions of Dr. Reddy's product were not disclosed